Zacks: Brokerages Expect Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) to Announce -$0.91 EPS

Wall Street analysts expect that Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) will announce ($0.91) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Rhythm Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.74) and the lowest estimate coming in at ($1.06). Rhythm Pharmaceuticals posted earnings of ($0.74) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 23%. The firm is scheduled to report its next quarterly earnings report on Friday, March 13th.

According to Zacks, analysts expect that Rhythm Pharmaceuticals will report full-year earnings of ($4.00) per share for the current financial year, with EPS estimates ranging from ($4.19) to ($3.82). For the next fiscal year, analysts expect that the company will post earnings of ($3.38) per share, with EPS estimates ranging from ($4.05) to ($3.06). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its earnings results on Friday, November 1st. The company reported ($1.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.06) by $0.02.

RYTM has been the topic of a number of research analyst reports. LADENBURG THALM/SH SH reiterated a “buy” rating and set a $43.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Monday, September 9th. BidaskClub upgraded Rhythm Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, October 22nd. Zacks Investment Research upgraded Rhythm Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 5th. Finally, Cowen reissued a “buy” rating and issued a $40.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Wednesday, September 25th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $38.80.

In other Rhythm Pharmaceuticals news, Director Todd Foley sold 102,682 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.78, for a total value of $2,236,413.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders have sold 418,709 shares of company stock worth $9,376,707. Insiders own 4.45% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC bought a new position in shares of Rhythm Pharmaceuticals in the third quarter valued at approximately $1,547,000. DekaBank Deutsche Girozentrale bought a new position in Rhythm Pharmaceuticals in the 2nd quarter valued at $564,000. Susquehanna International Group LLP acquired a new stake in shares of Rhythm Pharmaceuticals in the 2nd quarter valued at $328,000. Rice Hall James & Associates LLC boosted its holdings in Rhythm Pharmaceuticals by 172.5% in the second quarter. Rice Hall James & Associates LLC now owns 63,217 shares of the company’s stock valued at $1,391,000 after acquiring an additional 40,015 shares during the last quarter. Finally, Fosun International Ltd raised its holdings in Rhythm Pharmaceuticals by 37.0% during the 2nd quarter. Fosun International Ltd now owns 40,720 shares of the company’s stock worth $883,000 after purchasing an additional 11,000 shares during the last quarter. Institutional investors own 78.13% of the company’s stock.

Shares of NASDAQ:RYTM opened at $22.01 on Friday. The company has a 50 day moving average of $21.83 and a 200-day moving average of $22.15. The company has a quick ratio of 6.78, a current ratio of 6.78 and a debt-to-equity ratio of 0.02. Rhythm Pharmaceuticals has a twelve month low of $18.00 and a twelve month high of $31.94.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders.

Read More: What is the Shanghai Stock Exchange Composite Index?

Get a free copy of the Zacks research report on Rhythm Pharmaceuticals (RYTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.